Abstract
Multiple myeloma (MM) is a plasma cell malignancy characterized by the high capacity to induce osteolytic bone lesions. Bone destruction in MM mainly depends on the increase of osteoclast formation and activity that occurs in close contact with myeloma cells infiltration. The histomorphometric studies, performed in MM patients, have demonstrated that MM patients with high plasma cell infiltrate are also characterized by a lower number of osteoblasts and a decreased bone formation that contributes, to the development of bone lesion. In the last years the progress in acknowledge of the pathophysiology of MM-induced osteolysis leaded to identify new therapeutics targets in MM bone disease and developed new drugs in the treatment of patients with skeletal involvement
Keywords: Multiple Myeloma, osteoclast, RANKL, osteoblast, drugs
Current Pharmaceutical Biotechnology
Title: Targeting Pathways Mediating Bone Disease
Volume: 7 Issue: 6
Author(s): Nicola Giuliani, Francesca Morandi, Sara Tagliaferri and Vittorio Rizzoli
Affiliation:
Keywords: Multiple Myeloma, osteoclast, RANKL, osteoblast, drugs
Abstract: Multiple myeloma (MM) is a plasma cell malignancy characterized by the high capacity to induce osteolytic bone lesions. Bone destruction in MM mainly depends on the increase of osteoclast formation and activity that occurs in close contact with myeloma cells infiltration. The histomorphometric studies, performed in MM patients, have demonstrated that MM patients with high plasma cell infiltrate are also characterized by a lower number of osteoblasts and a decreased bone formation that contributes, to the development of bone lesion. In the last years the progress in acknowledge of the pathophysiology of MM-induced osteolysis leaded to identify new therapeutics targets in MM bone disease and developed new drugs in the treatment of patients with skeletal involvement
Export Options
About this article
Cite this article as:
Giuliani Nicola, Morandi Francesca, Tagliaferri Sara and Rizzoli Vittorio, Targeting Pathways Mediating Bone Disease, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116955
DOI https://dx.doi.org/10.2174/138920106779116955 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prostratin: An Overview
Mini-Reviews in Medicinal Chemistry Cellulitis-Like Sweet Syndrome Preceding Multiple Myeloma. A Case Report
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma
Current Drug Safety Structure and Function of CW Domain Containing Proteins
Current Protein & Peptide Science Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Current Cancer Drug Targets Evaluation of In-Vitro Multidrug Resistance Reversal Activities of HZ08 analogues with Improved Soluble Property
Letters in Drug Design & Discovery Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
Anti-Cancer Agents in Medicinal Chemistry Aberrant Regulation of Translation Initiation in Tumorigenesis
Current Molecular Medicine Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma
Current Drug Safety Treatment of Chronic Hypercalcemia
Medicinal Chemistry Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Targeting Histone Onco- Modifications Using Plant-Derived Products
Current Drug Targets The Role of Foxp3 in Regulatory T Cell Differentiation and Function
Current Immunology Reviews (Discontinued) Hyphenated Mass Spectrometry Techniques in the Diagnosis of Amyloidosis
Current Medicinal Chemistry Chemometric Evaluation of the Significance of Molecular Structural Descriptors on Binding of Acridinone Derivatives to DNA
Letters in Drug Design & Discovery Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets